Humacyte (NASDAQ:HUMA) Upgraded by Wall Street Zen to “Sell” Rating

Wall Street Zen upgraded shares of Humacyte (NASDAQ:HUMA) from a strong sell rating to a sell rating in a report released on Saturday morning.

Several other equities analysts also recently commented on the company. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research note on Tuesday, April 28th. Benchmark dropped their price objective on Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, January 21st. BTIG Research dropped their price objective on Humacyte from $3.00 to $2.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a research note on Friday, April 10th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Humacyte presently has an average rating of “Moderate Buy” and a consensus target price of $7.57.

Humacyte Price Performance

Shares of NASDAQ HUMA opened at $0.93 on Friday. Humacyte has a twelve month low of $0.55 and a twelve month high of $2.93. The stock’s 50 day moving average price is $0.85 and its 200-day moving average price is $1.06. The company has a market capitalization of $206.50 million, a PE ratio of -1.63 and a beta of 2.31. The company has a quick ratio of 2.95, a current ratio of 3.93 and a debt-to-equity ratio of 5.46.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%.The firm had revenue of $0.50 million for the quarter, compared to the consensus estimate of $1.46 million. On average, equities analysts anticipate that Humacyte will post -0.33 EPS for the current year.

Institutional Investors Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently bought and sold shares of HUMA. R Squared Ltd bought a new stake in Humacyte during the 4th quarter valued at $25,000. Atom Investors LP bought a new stake in Humacyte during the 4th quarter valued at $25,000. Truist Financial Corp bought a new stake in Humacyte during the 3rd quarter valued at $28,000. Prudential Financial Inc. bought a new stake in Humacyte during the 2nd quarter valued at $28,000. Finally, Financial Advisors Network Inc. bought a new stake in Humacyte during the 2nd quarter valued at $28,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.